Pfizer and AstraZeneca a Marriage Not to Be – Yet?
Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success in delivering the anticipated benefits is not good. Around 80% fail on the key measures of synergies, costs savings and growth in shareholder value. No matter if they are small medium or large, mergers hold high risks. Nonetheless,
Or if you're already a Pharma IQ member, sign in below to download. Sign In Join